Recombinant, octavalent group A streptococcal M protein vaccine

James B. Dale, Matthew Simmons, Elbert C. Chiang, Edna Y. Chiang

Research output: Contribution to journalArticlepeer-review

77 Scopus citations


One of the major obstacles to the development of group A streptococcal M protein vaccines is the multiplicity of M serotypes expressed by these organisms. In this study, we have constructed a recombinant, hybrid M protein that contains type-specific aminoterminal fragments of eight different M proteins. We show that the purified hybrid recombinant protein is immunogenic in rabbits and evokes antibodies that react with native M proteins from the respective streptococcal serotypes. In addition, the immune sera evoked by the octavalent protein opsonized six of the eight serotypes of streptococci, indicating that the majority of the M protein fragments contained protective epitopes that retained their native conformations in the hybrid protein, None of the antisera raised against the octavalent protein crossreacted with human heart tissue. These studies indicate that multivalent, hybrid M proteins may be used to elicit broadly protective immune responses against multiple serotypes of group A streptococci.

Original languageEnglish (US)
Pages (from-to)944-948
Number of pages5
Issue number10
StatePublished - Jul 1996
Externally publishedYes


  • M protein
  • Opsonic antibodies
  • Streptococcus pyogenes
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Recombinant, octavalent group A streptococcal M protein vaccine'. Together they form a unique fingerprint.

Cite this